IP Library › Granted Patent US 12,371,468
Granted Patent B2
US 12,371,468 · App. 17/429,602 · Granted Jul 29, 2025

Variable lymphocyte receptors that target the blood brain barrier and methods of use

Inventors: Eric V. Shusta (Madison, WI); Jason M. Lajoie (Madison, WI); Brantley R. Herrin (Madison, WI)
Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION; EMORY UNIVERSITY
C07K14/7051A61K47/68C07K16/2881A61K2039/505C07K2317/565C07K2317/569C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,468
App. No.
17/429,602
Granted
Jul 29, 2025
Kind
B2
Abstract

The present disclosure provides isolated polypeptides comprising variable lymphocyte receptors that specifically bind the blood brain barrier, compositions, and methods of use.

Claims (42)

1. An isolated polypeptide antigen-binding fragment thereof comprising a variable lymphocyte receptor (VLR) amino acid sequence comprising the following regions:

(i) EVRCESRSLASVPA (SEQ ID NO:5) and RRLHLHR (SEQ ID NO:6), or TVDCSGKSLASVPT (SEQ ID NO: 13) and QILRLYRNQI (SEQ ID NO:14), or TVDCSGKSLASVPT (SEQ ID NO:16) and RWLHLHR (SEQ ID NO:17),

(ii) YLNLGG (SEQ ID NO:7),

(iii) ELKLYS (SEQ ID NO:8),

(iv) HLDLSK (SEQ ID NO:9),

(v) HAYLFG (SEQ ID NO: 10), and

(vi) SIVMRWDGKAVNDPDSAK (SEQ ID NO:11).

2. The isolated polypeptide or antigen-binding fragment thereof of claim 1 , wherein the isolated polypeptide or antigen-binding fragment thereof is able to specifically bind to and cross the blood brain barrier in vivo, and wherein the VLR amino acid sequence comprises the regions:

(a) EVRCESRSLASVPA (SEQ ID NO:5), RRLHLHR (SEQ ID NO:6), YLNLGG (SEQ ID NO:7), ELKLYS (SEQ ID NO:8), HLDLSK (SEQ ID NO:9), HAYLFG (SEQ ID NO:10), and SIVMRWDGKAVNDPDSAK (SEQ ID NO: 11), or

(b) TVDCSGKSLASVPT (SEQ ID NO: 16); RWLHLHR (SEQ ID NO: 17), YLNLGG (SEQ ID NO:7), ELKLYS (SEQ ID NO:8), HLDLSK (SEQ ID NO:9), HAYLFG (SEQ ID NO:10), and SIVMRWDGKAVNDPDSAK (SEQ ID NO: 11).

3. The isolated polypeptide or antigen-binding fragment thereof of claim 1 , wherein the isolated polypeptide or antigen-binding fragment thereof is able to specifically bind to brain microvascular endothelial cells (BMECs) surface, and wherein the VLR amino acid sequence comprises the regions:

(i) TVDCSGKSLASVPT (SEQ ID NO: 13),

(ii) QILRLYRNQI (SEQ ID NO: 14),

(iii) YLNLGG (SEQ ID NO:7),

(iv) ELKLYS (SEQ ID NO:8),

(v) HLDLSK (SEQ ID NO:9),

(vi) HAYLFG (SEQ ID NO: 10), and

(vii) SIVMRWDGKAVNDPDSAK (SEQ ID NO:11).

4. The isolated polypeptide or antigen-binding fragment thereof of claim 1 , wherein the VLR amino acid sequence is selected from the group consisting of VLR 11 (SEQ ID NO:1), VLR30 (SEQ ID NO:2), VLR46 (SEQ ID NO:3), and an amino acid sequence with at least 95% sequence identity to SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.

5. The isolated polypeptide or antigen-binding fragment thereof of claim 1 , wherein the VLR amino acid sequence is directly or indirectly linked to an agent.

6. The isolated polypeptide or antigen-binding fragment thereof of claim 5 , wherein the agent is selected from the group consisting of a therapeutic agent, a pharmaceutical agent, a diagnostic agent, an imaging agent, a detection agent, an immunological therapeutic construct, and a combination thereof.

7. The isolated polypeptide or antigen-binding fragment thereof of claim 5 , wherein the agent is a polypeptide directly or indirectly fused to the isolated polypeptide as a fusion protein.

8. The isolated polypeptide or antigen-binding fragment thereof of claim 5 , wherein the agent is a portion of a fragment crystallizable region (Fc) of an antibody.

9. The isolated peptide or antigen-binding fragment thereof of claim 8 , wherein the Fc is from human IgG.

10. A composition comprising the isolated peptide or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

11. An isolated nucleic acid sequence encoding the isolated polypeptide or antigen-binding fragment thereof of claim 1 .

12. A vector comprising the isolated nucleic acid sequence of claim 11 .

13. A cell able to express the isolated polypeptide or antigen-binding fragment thereof of claim 1 .

14. A method of targeting an agent to the blood brain barrier (BBB) of a subject, the method comprising:

(a) administering to the subject the isolated polypeptide or antigen-binding fragment thereof of claim 5 , wherein the VLR amino acid sequence is directly or indirectly linked to the agent.

15. The method of claim 14 , wherein the agent is:

(a) delivered to the surface of the BBB after targeting; and/or

(b) able to cross the BBB after targeting.

16. The method of claim 14 , wherein the agent is selected from the group consisting of a therapeutic agent, a pharmaceutical agent, a diagnostic agent, an imaging agent, a detection agent, an immunological therapeutic construct, and a combination thereof.

17. A method of detecting or imaging blood brain barrier endothelial cells (BMECs), the method comprising:

(a) contacting the BMECs with the isolated polypeptide or antigen-binding fragment thereof of claim 5 , and

(b) detecting or imaging the BMECs.

18. The method of claim 17 , wherein the contacting step comprises administering the isolated polypeptide to a subject and wherein the detecting or imaging step is performed in vivo in a subject.

19. The method of claim 18 , wherein the isolated polypeptide or antigen-binding fragment thereof is administered to the subject systemically.

20. The method of claim 17 , wherein the detecting or imaging step comprises PET or MRI imaging.

21. The isolated polypeptide or antigen-binding fragment thereof of claim 1 , wherein the VLR amino acid sequence is capable of binding a Neu5Acα2-6Galβ1-4GlcNAcβ1-3Gal motif or a Neu5Acα2-6Galβ1-4GlcNAcβ1-3GalNAc motif on the BBB.

22. The isolated polypeptide or antigen-binding fragment thereof of claim 21 , wherein the isolated polypeptide or antigen-binding fragment thereof is capable of engaging and trafficking within the BBB endothelium.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2024
From: HERRIN, BRANTLEY R
To: EMORY UNIVERSITY
Reel/Frame 067944/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2024
From: SHUSTA, ERIC; LAJOIE, JASON
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 067350/0715 →
Continuity (2)
Provisional Application 62804003 · Feb 11, 2019
Related Publication 20220204583A1 · Jun 30, 2022
References Cited (100)
US 8039588B2 · Pancer et al. · 2011 [cited by applicant]
US 8212018B2 · Pancer et al. · 2012 [cited by applicant]
US 9127087B2 · Pancer et al. · 2015 [cited by applicant]
US 10036747B2 · Pancer et al. · 2018 [cited by applicant]
US 20170081385A1 · Herrin et al. · 2017 [cited by applicant]
WO 2006083275A2 · 2006 [cited by applicant]
WO WO2006083275 · 2006 [cited by examiner]
WO 2013078425A1 · 2013 [cited by applicant]
WO 2015168469A1 · 2015 [cited by applicant]
WO 2015174869A1 · 2015 [cited by applicant]
WO 2020132301A1 · 2020 [cited by applicant]
Bhattacharya et al., PLoS One 12(3): e0171355. https://doi.org/10.1371/journal.pone.0171355; 22 pages total (Year: 2017). [cited by examiner]
Fenton et al., Medicinal Chemistry Research (2020) 29:1133-1146 (Year: 2020). [cited by examiner]
Alder et al., Science (2005) 310, 1970-1973 (Year: 2005). [cited by examiner]
Abbott,N. J., A. A. K. Patabendige, D. E. M. Dolman, S. R. Yusof, D. J. Begley, Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25 (2010). [cited by applicant]
Brown, B. Badie, M. E. Barish, L. Weng, J. R. Ostberg, W.-C. Chang, A. Naranjo, R. Starr, J. Wagner, C. Wright, Y. Zhai, J. R. Bading, J. A. Ressler, J. Portnow, M. D'Apuzzo, S. J. Forman, M. C. Jensen, Bioactivity and … [cited by applicant]
Brown, Peptidic tumor targeting agents: The road from phage display peptide selections to clinical applications. Curr. Pharm. Des. 16, 1040-1054 (2010). [cited by applicant]
Burns, T. M. Malott, K. J. Metcalf, B. J. Hackel, J. R. Chan, E. V. Shusta, Directed evolution of brain-derived neurotrophic factor for improved folding and expression in [cited by applicant]
Calabria, A. R. & Shusta, E. V. A genomic comparison of in vivo and in vitro brain microvascular endothelial cells. J. Cereb. Blood Flow Metab. 28, 135-48 (2008). [cited by applicant]
Castaldo, C. et al. Cardiac fibroblast-derived extracellular matrix (biomatrix) as a model for the studies of cardiac primitive cell biological properties in normal and pathological adult human heart. Biomed Res. Int. (… [cited by applicant]
Chao, G. et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1, 755-768 (2006). [cited by applicant]
Chia, P. Z. C., Gunn, P. & Gleeson, P. A. Cargo trafficking between endosomes and the trans-Golgi network. Histochem. Cell Biol. 140, 307-15 (2013). [cited by applicant]
Clark et al. “Neurovascular-targeting antibodies discovered using yeast biopanning enhance drug delivery and improve survival for glioblastoma,” Cancer Res (2018) 78 (13_Supplement): 1764. (Abstract). [cited by applicant]
Collins, B. C. et al. Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates. Structure 25, 1-12 (2017). [cited by applicant]
Crapo, T. W. Gilbert, S. F. Badylak, An overview of tissue and whole organ decellularization processes. Biomaterials 32, 3233-3243 (2011). [cited by applicant]
Daneman, R. The blood-brain barrier in health and disease. Ann. Neurol. 72, 648-72 (2012). [cited by applicant]
Gadkar, K. et al. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain. Eur. J. Pharm. Biopharm. 101, 53-61 (2016). [cited by applicant]
Gray, M. J. McGuire, K. C. Brown, A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLOS One 8, e72938 (2013). [cited by applicant]
Gunn, R. J., Herrin, B. R., Acharya, S., Cooper, M. D. & Wilson, I. A. VLR Recognition of TLR5 Expands the Molecular Characterization of Protein Antigen Binding by Non-Ig based Antibodies. J. Mol. Biol. 430, 1350-1367 (… [cited by applicant]
Gupta, V. P. Torchilin, Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immun… [cited by applicant]
Herrin et al., “Structure and specificity of lamprey monoclonal antibodies,” Proc Natl Acad Sci U S A Feb. 12, 2008;105(6):2040-5. [cited by applicant]
Herrin, M. D. Cooper, Alternative adaptive immunity in jawless vertebrates. J. Immunol. 185, 1367-1374 (2010). [cited by applicant]
Holodinsky, A. Y. X. Yu, Z. A. Assis, A. S. Al Sultan, B. K. Menon, A. M. Demchuk, M. Goyal, M. D. Hill, History, evolution, and importance of emergency endovascular treatment of acute ischemic stroke. Curr. Neurol. Neu… [cited by applicant]
Hong, M. Z. Ma, J. C. Gildersleeve, S. Chowdhury, J.J. BarchiJr., R. A. Mariuzza, M. B. Murphy, L. Mao, Z. Pancer, Sugar-binding proteins from fish: Selection of high affinity “lambodies” that recognize biomedically rel… [cited by applicant]
Hwang, J.-H. Ryou, J. R. Oh, J. W. Han, T. K. Park, H.-S. Kim, Anti-human VEGF repebody effectively suppresses choroidal neovascularization and vascular leakage. PLOS One 11, e0152522 (2016). [cited by applicant]
Iacopetta, B. J. & Morgan, E. H. The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. J. Biol. Chem. 258, 9108-15 (1983). [cited by applicant]
Kasahara et al., “Two Forms of Adaptive Immunity in Vertebrates: Similarities and Differences.” Adv in Immunol. (2014). [cited by applicant]
Kumar, P. et al. Macromolecularly crowded in vitro microenvironments accelerate the production of extracellular matrix-rich supramolecular assemblies. Sci. Rep. 5, 8729 (2015). [cited by applicant]
Kuznetsov, R. K. Puri, Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: Suppression of IL-13 binding by IL-2 receptor gamma chain. Biophys. J. 77, 154-172 (1999). [cited by applicant]
Lajoie, J. M. & Shusta, E. V. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 55, 613-31 (2015). [cited by applicant]
Lamsam, E. Johnson, I. D. Connolly, M. Wintermark, M. Hayden Gephart, A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy. Neurosurg. Focus 44, E10 (2018). [cited by applicant]
Lee, H. J. Kim, C.-S. Yang, H.-H. Kyeong, J.-M. Choi, D.-E. Hwang, J.-M. Yuk, K. Park, Y. J. Kim, S.-G. Lee, D. Kim, E.-K. Jo, H.-K. Cheong, H.-S. Kim, A high-affinity protein binder that blocks the IL-6/STAT3 signaling… [cited by applicant]
Lidinsky, W. A. & Drewes, L. R. Characterization of the Blood-Brain Barrier: Protein Composition of the Capillary Endothelial Cell Membrane. J. Neurochem. 41, 1341-1348 (1983). [cited by applicant]
Lockman, R. K. Mittapalli, K. S. Taskar, V. Rudraraju, B. Gril, K. A. Bohn, C. E. Adkins, A. Roberts, H. R. Thorsheim, J. A. Gaasch, S. Huang, D. Palmieri, P. S. Steeg, Q. R. Smith, Heterogeneous blood—tumor barrier per… [cited by applicant]
Mann, P. Scodeller, S. Hussain, J. Joo, E. Kwon, G. B. Braun, T. Mölder, Z.-G. She, V. R. Kotamraju, B. Ranscht, S. Krajewski, T. Teesalu, S. Bhatia, M. J. Sailor, E. Ruoslahti, A peptide for targeted, systemic delivery… [cited by applicant]
McCaffrey,G., T. P. Davis, Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery. J. Invest. Med. 60, … [cited by applicant]
Michel, C. C. Transport of macromolecules through microvascular walls. Cardiovasc. Res. 32, 644-53 (1996). [cited by applicant]
Minagar, J. S. Alexander, Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540-549 (2003). [cited by applicant]
Moos, T. & Morgan, E. H. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J. Neurochem. 79, 119-29 (2001). [cited by applicant]
Murugandam, A., Tanha, J., Narang, S. & Stanimirovic, D. Selection of phage displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16 (2002). [cited by applicant]
Nance, K. Timbie, G. W. Miller, J. Song, C. Louttit, A. L. Klibanov, T.-Y. Shih, G. Swaminathan, R. J. Tamargo, G. F. Woodworth, J. Hanes, R. J. Price, Non-invasive delivery of stealth, brain-penetrating nanoparticles a… [cited by applicant]
Nico, D. Ribatti, Morphofunctional aspects of the blood-brain barrier. Curr. Drug Metab. 13, 50-60 (2012). [cited by applicant]
Niewoehner, J. et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. Neuron 81, 49-60 (2014). [cited by applicant]
Nitta et al., Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161(3):653-60 (2003). [cited by applicant]
Obermeier, A. Verma, R. M. Ransohoff, The blood-brain barrier. Handb. Clin. Neurol. 133, 39-59 (2016). [cited by applicant]
Oh, S. Fakurnejad, E. T. Sayegh, A. J. Clark, M. E. Ivan, M. Z. Sun, M. Safaee, O. Bloch, C. D. James, A. T. Parsa, Immunocompetent murine models for the study of glioblastoma immunotherapy. J. Transl. Med. 12, 107 (201… [cited by applicant]
Ostrom, H.Gittleman, J. Fulop, M. Liu, R. Blanda, C. Kromer, Y. Wolinsky, C. Kruchko, J. S. Barnholtz-Sloan, CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the united states in 2… [cited by applicant]
Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3-14 (2005). [cited by applicant]
Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-6 (1996). [cited by applicant]
Pellegatta, B. Savoldo, N. Di Ianni, C. Corbetta, Y. Chen, M. Patané, C. Sun, B. Pollo, S. Ferrone, F. DiMeco, G. Finocchiaro, G. Dotti, Constitutive and TNF□-inducible expression of chondroitin sulfate proteoglycan 4 i… [cited by applicant]
Piatesi, A. et al. Directed evolution for improved secretion of cancer-testis antigen NY ESO-1 from yeast. Protein Expr. Purif. 48, 232-242 (2006). [cited by applicant]
Ponsel, D., Neugebauer, J., Ladetzki-Baehs, K. & Tissot, K. High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 16, 3675-700 (2011). [cited by applicant]
Preusser, M. Lim, D. A. Hafler, D. A. Reardon, J. H. Sampson, Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 11, 504-514 (2015). [cited by applicant]
Requirement for Restriction for U.S. Appl. No. 17/414,581, mailed Apr. 20, 2023. [cited by applicant]
Saito G, Swanson J A, Lee K D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities, Adv Drug Deliv Rev. Feb. 10, 2003; 55(2):199-215. [cited by applicant]
Sata, T et al., “Dectection of the Neu5Ac (a2,3) Gal (b1,4) GlcNAc Sequence within the Leukoagglutinin from Maackia amurensis: Light and Electron Microscopic Demonstration of Differential Tissue Expression of t Terminal… [cited by applicant]
Scott, D. W. & Patel, R. P. Endothelial heterogeneity and adhesion molecules N-glycosylation: implications in leukocyte trafficking in inflammation. Glycobiology 23, 622-33 (2013). [cited by applicant]
Shi et al., “Rapid endothelial cytoskeletal reorganization enables early blood-brain barrier disruption and long-term ischaemic reperfusion brain injury,” Nat Commun . Jan. 27, 2016;7:10523. [cited by applicant]
Shusta, E, “Using Lamprey Antibodies to Profile the Blood-Brain Barrier”, National Institute of Health (2015). [cited by applicant]
Siegel, K. D. Miller, A. Jemal, Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015). [cited by applicant]
Silber, P. M., Gandolfi, A. J. & Brendel, K. Adaptation of a gamma-glutamyl-transferase transpeptidase assay to microtiter plates. Anal. Biochem. 158, 68-71 (1986). [cited by applicant]
Steiner, P. Forrer, A. Plückthun, Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J. Mol. Biol. 382, 1211-1227 (2008). [cited by applicant]
Stern, L. A. et al. Geometry and expression enhance enrichment of functional yeast displayed ligands via cell panning. Biotechnol. Bioeng. (2016). doi:10.1002/bit.26001. [cited by applicant]
Stutz, C. C., et al. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 9, 664-74 (2014). [cited by applicant]
Stutz, C. C., Zhang, X. & Shusta, E. V. Combinatorial approaches for the identification of brain drug delivery targets. Curr. Pharm. Des. 20, 1564-76 (2014). [cited by applicant]
Sugano et al., Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice Cancer Research 60, 6942-6… [cited by applicant]
Sukhanova et al., “Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes,” Nanomedicine 8(4): 516-525, 2012. [cited by applicant]
Swanson, P. A. Clark, R. R. Zhang, I. K. Kandela, M. Farhoud, J. P. Weichert, J. S. Kuo, Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection. Neurosurgery 76, 115-124 (2015). [cited by applicant]
Tillotson, B. J., Cho, Y. K. & Shusta, E. V. Cells and cell lysates: A direct approach for engineering antibodies against membrane proteins using yeast surface display. Methods 60, 27-37 (2013). [cited by applicant]
Tillotson, B. J., de Larrinoa, I. F., Skinner, C. A., Klavas, D. M. & Shusta, E. V. Antibody affinity maturation using yeast display with detergent-solubilized membrane proteins as antigen sources. Protein Eng. Des. Sel… [cited by applicant]
Trail P A, King H D, Dubowchik G M, Monoclonal antibody drug immunoconjugates for targeted treatment of cancer, Cancer Immunol Immunother. May 2003; 52(5):328-37. [cited by applicant]
Ueno, M. et al. Transporters in the brain endothelial barrier. Curr. Med. Chem. 17, 1125-38 (2010). [cited by applicant]
Umlauf, “Identification and Development of Variable Lymphocyte Targeting Ligands for Glioblastoma,” PEGS Boston, 2018 (Presentation). [cited by applicant]
Umlauf, BJ et al., “Identification of variable lymphocyte receptors that can target therapeutics to pathologically exposed brain extracellular matrix.” Science Advances, May 15, 2019, vol. 5, No. eaau4245, pp. 1-12. [cited by applicant]
Umlauf, K. A. Mix, V. A.Grosskopf, R. T. Raines, E. V. Shusta, Site-specific antibody functionalization using tetrazine-styrene cycloaddition. Bioconjug. Chem. 29, 1605-1613 (2018). [cited by applicant]
Van De Broek et al., “Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy,” ACS Nano 5(6): 4319-4328, 2011. [cited by applicant]
Van Den Berg, B. M., Vink, H. & Spaan, J. A. E. The endothelial glycocalyx protects against myocardial edema. Circ. Res. 92, 592-4 (2003). [cited by applicant]
Venkataraman, M., Sasisekharan, R. & Raman, R. Glycan Array Data Management at Consortium for Functional Glycomics. in Methods in molecular biology (Clifton, N.J.) 1273, 181-190 (2015). [cited by applicant]
Vogel, J. et al. Influence of the endothelial glycocalyx on cerebral blood flow in mice. J. Cereb. Blood Flow Metab. 20, 1571-8 (2000). [cited by applicant]
Wang, E. V. Shusta, The use of scFv-displaying yeast in mammalian cell surface selections. J. Immunol. Methods 304, 30-42 (2005). [cited by applicant]
Wang, X. X., Cho, Y. K. & Shusta, E. V. Mining a yeast library for brain endothelial cell binding antibodies. Nat. Methods 4, 143-145 (2007). [cited by applicant]
Waters and Shusta. “The variable lymphocyte receptor as an antibody alternative.” Curr Opin Biotechnol. Aug. 2018; 52:74-79. [cited by applicant]
Whitehead et. al. “Artificial Membrane Fusion Triggered by Strain-Promoted Alkyne-Azide Cycloaddition” Bioconjugate Chem. Apr. 28, 2017, 923-932 DOI: 10.1021/acs.bioconjchem.6b00578. [cited by applicant]
Williams, R. L. et al. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell 57, 1053-63 (1989). [cited by applicant]
Woodworth, G. P. Dunn, E. A. Nance, J. Hanes, H. Brem, Emerging insights into barriers to effective brain tumor therapeutics. Front. Oncol. 4, 126 (2014). [cited by applicant]
Wu A M, Senter P D, Arming antibodies: prospects and challenges for immunoconjugates, Nat Biotechnol. Sep. 2005; 23(9):1137-46. [cited by applicant]
Yu, C. et al. Identification of human plasma cells with a lamprey monoclonal antibody. JCI Insight 1 (2016). [cited by applicant]
Yu, Y. J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3 (2011). [cited by applicant]
Yu, Y. J. et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med. 6 (2014). [cited by applicant]
Zhou, H., Zhang, Y.-L., Lu, G., Ji, H. & Rodi, C. P. Recombinant antibody libraries and selection technologies. N. Biotechnol. 28, 448-52 (2011). [cited by applicant]